कृपया अन्य खोज का प्रयास करें
Egetis Therapeutics AB (publ), a pharmaceutical company, focuses on projects in late-stage development for the treatment of serious diseases with unmet medical needs in the orphan drug segment. Its products pipeline includes Aladote, a drug to reduce the risk of acute liver injury associated with acetaminophen/paracetamol poisoning, which is in phase IIb/III clinical trial; and Emcitate, a drug for the treatment of MCT8 deficiency, a highly debilitating rare disease with no available treatment. The company was formerly known as PledPharma AB (publ) and changed its name to Egetis Therapeutics AB (publ) in December 2020. Egetis Therapeutics AB (publ) was incorporated in 2006 and is based in Stockholm, Sweden.
नाम | आयु | पहले | शीर्षक |
---|---|---|---|
Thomas Lonngren | 72 | 2021 | Chairman of the Board |
Behshad Sheldon | 60 | 2023 | Independent Director |
Gunilla Osswald | 63 | 2017 | Independent Director |
Elisabeth Svanberg | 63 | 2017 | Independent Director |
Laura James | - | 2018 | Member of Scientific Advisory Board |
Richard C. Dart | - | 2018 | Member of Scientific Advisory Board |
James Dear | - | - | Member of Scientific Advisory Board |
Peder Walberg | 50 | 2020 | Director |
Mats Peter Blom | 59 | 2021 | Director |
क्या आप सच में %USER_NAME% को ब्लॉक करना चाहते हैं?
ऐसा करके, आप और %USER_NAME% नहीं देख पाएंगे किसी अन्य के Investing.com की पोस्ट में से कोई भी।
%USER_NAME% को सफलतापूर्वक आपकी ब्लॉक सूची में जोड़ लिया गया है
क्योंकि आपने इस व्यक्ति को अनब्लॉक कर दिया है, आपको ब्लॉक को रिन्यू करने से पहले 48 घंटे प्रतीक्षा करनी होगी।
मुझे लगता है कि यह टिपण्णी:
धन्यवाद!
आपकी रिपोर्ट समीक्षा के लिए हमारे मॉडरेटर को भेजी गई है